Securities Code: 4506

Supplementary Data of Financial Results for the Year Ended－ March 31, 2007

May 10, 2007

Dainippon Sumitomo Pharma Co., Ltd.

- Forecasts provided in this document are based on the management's assumptions and beliefs, made in light of information available up to the day of announcement. Actual financial results may differ materially from those presented in this document, being dependent upon a number of factors.
- All values are rounded. Therefore totals may not be consistent with aggregated figures.
- For figures shown as "simple totals", the simple totals of the former Sumitomo Pharmaceutical figures for the September 2005 period were used for the March 2006 period.

I. Consolidated Financial Highlights

1. Highlights of the Statements of Income (Billions of Yen)

	Year ended 3/31/06	Year ended 3/31/07	Change (%)	Year ending 3/31/08 (Forecast)	Change (%)	Six months ending 9/30/07 (Forecast)	Change (%)
Net sales	245.8	261.2	6.3	273.0	4.5	133.0	4.8
Cost of sales	130.4	99.3	(23.8)	102.0	2.7		
Selling, general and administrative expenses	86.5	116.3	34.5	125.0	7.5		
[R&D expenditures]	[29.6]	[40.9]	[37.9]	[48.0]	[17.4]		
Operating income	28.9	45.6	57.7	46.0	1.0	22.0	7.5
Recurring income	27.2	43.2	58.5	44.0	1.9	21.0	7.3
Net income	15.4	22.6	47.0	26.0	15.0	12.4	30.8

Note: Cost of Sales includes provision for (reversal of) reserve for sales returns.

Earnings per share (yen)	54.57	56.86	65.41
Return on equity (ROE)	7.3%	7.6%	8.3%
Payout ratio	22.0%	24.6%	27.5%

(Reference) Comparison of simple totals (Billions of Yen)

	Year ended 3/31/06	Year ended 3/31/07	Change (%)
Net sales	318.2	261.2	(17.9)
Cost of Sales	152.1	99.3	(34.7)
Selling, general and administrative expenses	121.4	116.3	(4.2)
[R&D expenditures]	[41.8]	[40.9]	[(2.3)]
Operating income	44.7	45.6	2.0
Recurring income	42.2	43.2	2.3
Net income	25.3	22.6	(10.5)

Note: Cost of Sales includes provision for (reversal of) reserve for sales returns.

2. Highlights of the Balance Sheet (Billions of Yen)

	As of 3/31/06 (A)	As of 3/31/07 (B)	(B) - (A)
Total assets	393.0	382.5	(10.4)
Net assets	288.6	306.0	17.4
Shareholders' equity	287.8	305.1	17.3
Shareholders' equity ratio	73.2%	79.8%	

Note: Past year's results have been rearranged in the current period display section.

3. Capital Expenditures and Depreciation (Billions of Yen)

	Year ended 3/31/06	Year ended 3/31/07	Change	Year ending 3/31/08 (Forecast)	Change
Capital expenditures (including intangible fixed assets)	6.6	9.5	2.9	17.5	8.0
Depreciation and amortization	8.6	11.3	2.7	11.7	0.4

- Major capital expenditure projects for the year ending March 31, 2008

Construction of a new solid preparation building at the Suzuka Plant:

¥10.0 billion (total budget: ¥10.0 billion completed in October 2007)

Renovation of Experimental animal facility of Central Research Laboratories:

¥0.55 billion (total budget: ¥0.55 billion completed in January 2008)

4. Highlights of the Statements of Cash Flows (Billions of Yen)

	Year ended 3/31/06	Year ended 3/31/07	Change
Cash flows from operating activities	9.1	37.9	28.8
Cash flows from investing activities	(10.4)	(19.7)	(9.2)
Cash flows from financing activities	(7.3)	(7.8)	(0.5)
Cash and cash equivalents at end of period	71.3	81.7	10.4

II. Consolidated Statements of Income

1. Statements of Income (Billions of Yen)

	Year ended 3/31/06	Year ended 3/31/06 (simple totals)	Year ended 3/31/07	Change
Net sales	245.8	318.2	261.2	(57.0)
Cost of Sales	130.4	152.1	99.3	(52.8)
Gross profit	115.3	166.1	161.9	(4.2)
Selling, general and administrative expenses	86.5	121.4	116.3	(5.1)
[R&D expenditures]	[29.6]	[41.8]	[40.9]	[(1.0)]
Operating income	28.9	44.7	45.6	0.9
Non-operating income	1.7	2.0	1.9	(0.2)
Non-operating expenses	3.4	4.5	4.3	(0.3)
Recurring income	27.2	42.2	43.2	1.0
Extraordinary income	4.4	8.9	—	(8.9)
Gains on sale of investment securities	1.9	1.9	—	
Gains on sale of property, plant and equipment	1.8	1.8	—	
Gains on transfer of the substitutional portion of the government pension program	0.8	0.8	—	
Gains on business transfers	—	4.5	—	
Extraordinary expenses	6.0	9.8	4.8	(5.1)
Additional retirement expenses for employees	—	0.6	2.9	
Expenses related to litigation	—	—	1.0	
Loss on reform of retirement benefits plan	—	—	0.6	
Loss on impairment of fixed assets	—	—	0.2	
Expenses related to merger	5.8	8.2	—	
Loss on business restructuring	0.2	1.0	—	
Income before income taxes and minority interests	25.7	41.3	38.4	(2.9)
Income taxes: Current	10.4	16.2	12.0	(4.1)
Income taxes: Deferred	(0.1)	(0.2)	3.7	3.9
Minority interests	0.1	0.1	0.1	(0.0)
Net income	15.4	25.3	22.6	(2.7)

- Dissolving partnerships (Abbott Japan, etc.)
- Decrease in industrial property revenues
- NHI drug price revision
- Sales growth of 4 strategic products and others

- Improvement of Cost-to-sales ratio due to change of product mix, etc.
- Cost-to-sales ratio: 47.8% → 38.0%

- Decrease in industrial property revenues
- NHI drug price revision
- Sales growth of priority products

- Reduced labor costs
- Reduced promotional costs and transport costs, etc.

- Expenses related to litigation of license agreement on new-quinolone compound

- Loss on impairment of idle fixed assets in Suzuka and Ibaraki Plants

Note: Cost of Sales includes provision for (reversal of) reserve for sales returns.
Change is based on comparison with Year ended 3/31/06 (simple totals).

2. Segment Information (Billions of Yen)

	Year ended 3/31/06			Year ended 3/31/07			Year ending 3/31/08 (Forecast)			Six months ending 9/30/07 (Forecast)		
	Pharma-ceuticals	Other Products	Total	Pharma-ceuticals	Other Products	Total	Pharma-ceuticals	Other Products	Total	Pharma-ceuticals	Other Products	Total
Net sales	192.6	53.2	245.8	206.3	55.0	261.2	217.0	56.0	273.0	106.5	26.5	133.0
Operating income	27.7	1.1	28.9	44.4	1.2	45.6						

3. Sales of Major Products

Domestic Sales (Billions of Yen)

Brand name (Generic name) Therapeutic indication	Year ended 3/31/06	Year ended 3/31/07	Year ending 3/31/08 (Forecast)
AMLODIN® (amlodipine) Therapeutic agent for hypertension and angina pectoris	56.8	59.2	66.0
GASMOTIN® (mosapride citrate) Gastroprokinetic	16.3	18.5	21.0
MEROPEN® (meropenem) Carbapenem antibiotic	14.1	14.3	15.5
PRORENAL® (limaprost alfadex) Vasodilator	12.6	13.8	16.0
EBASTEL® (ebastine) Antiallergic	11.3	11.4	11.0
SUMIFERON® (interferon-α NAMALWA)) Natural alpha interferon	6.0	6.4	6.9
QVAR™ (beclomethasone dipropionate) Bronchial asthma	4.2	4.8	5.6
GROWJECT® (somatropin) Growth hormone	4.9	4.8	5.2
DOPS® (droxidopa) Norepinephrine-activating neural function ameliorant	4.7	4.5	4.1
GLIMICRON® (gliclazide) Oral hypoglycemic	4.7	4.4	4.3
TAGAMET® (cimetidine) H_2-receptor antagonist	4.6	3.9	3.6
EXCEGRAN® (zonisamide) Antiepileptic	3.6	3.6	3.5
ALMARL® (arotinolol) Therapeutic agent for hypertension, angina pectoris and arrhythmia	3.7	3.5	3.0
LULLAN® (perospirone) Antipsychotic	3.0	3.1	3.4
SEDIEL® (tandospirone) Serotonin-agonist antianxiety drug	3.1	3.0	2.9
KLARICID® (clarithromycin) Macrolide antibiotic	19.0	—	—
ENSURE LIQUID® Enteral nutrition	13.8	—	—
SYNAGIS® (palivizumab) Monoclonal antibody	12.0	—	—

Brand name (Generic name) Therapeutic indication	Year ended 3/31/06	Year ended 3/31/07	Year ending 3/31/08 (Forecast)
SEVOFRANE® (sevoflurane) Anesthetic	4.4	—	—
LOPEMIN® (loperamide hydrochloride) Antidiarrheal	3.1	—	—

Exports (Billions of Yen)

Brand name (Generic name) Therapeutic indication	Year ended 3/31/06	Year ended 3/31/07	Year ending 3/31/08 (Forecast)
MEROPENEM (meropenem trihydrate) Carbapenem antibiotic	12.9	16.1	15.9
MOSAPRIDE (mosapride citrate) Gastroprokinetic	0.9	1.4	1.6
ZONISAMIDE (zonisamide) Antiepileptic	2.4	0.8	0.2
Others	0.6	0.8	0.7
Export total	(simple totals) 16.8	19.1	18.4

Industrial Property Revenues (Billions of Yen)

	Year ended 3/31/06	Year ended 3/31/07	Year ending 3/31/08 (Forecast)
Industrial property revenues	(simple totals) 8.5	3.9	2.3

Overseas sales (% of net sales): 8.4%

Note: Overseas sales include exports and a part of industrial property revenues.

4. Selling, General and Administrative Expenses

(Billions of Yen)

	Year ended 3/31/06	% of net sales	Year ended 3/31/07	% of net sales	Year ending 3/31/08 (Forecast)	% of net sales
Net sales	245.8	100.0	261.2	100.0	273.0	100.0
Labor costs	25.7	—	32.1	—		
Advertising and promotion costs	3.4	—	5.0	—		
Sales promotion costs	6.7	—	9.5	—		
Others	21.0	—	28.9	—		
Selling, general and administrative expenses less R&D expenditures	56.8	23.1	75.4	29.0	77.0	28.2
R&D expenditures	29.6	12.1	40.9	15.6	48.0	17.6
Total	86.5	35.2	116.3	44.6	125.0	45.8

(Reference) Simple Totals

(Billions of Yen)

	Year ended 3/31/06	% of net sales	Year ended 3/31/07	% of net sales
Net sales	318.2	100.0	261.2	100.0
Selling, general and administrative expenses less R&D expenditures	79.6	25.0	75.4	29.0
R&D expenditures	41.8	13.1	40.9	15.6
Total	121.4	38.2	116.3	44.6

III. Consolidated Balance Sheets

ASSETS

(Billions of Yen)

	As of 3/31/06 (A)	As of 3/31/07 (B)	(B) - (A)
[Assets]	393.0	382.5	(10.4)
Current assets:	249.7	234.3	(15.4)
Cash and time deposits	60.3	55.8	(4.6)
Notes and accounts receivable	114.5	88.8	(25.7)
Marketable securities	14.0	28.0	14.0
Inventories	44.1	45.0	0.8
Deferred tax assets	11.1	10.4	(0.7)
Others	5.8	6.6	0.9
Allowance for doubtful receivables	(0.1)	(0.2)	(0.1)
Fixed assets:	143.2	148.2	5.0
Property, plant and equipment	68.3	65.2	(3.1)
Buildings and structures	37.7	37.4	(0.3)
Machinery, equipment and carriers	14.1	11.3	(2.8)
Land	10.0	10.0	(0.0)
Construction in progress	1.6	1.9	0.3
Others	4.9	4.6	(0.3)
Intangible fixed assets	6.0	6.7	0.8
Investments and other assets	68.9	76.3	7.3
Investment securities	48.9	52.0	3.1
Deferred tax assets	0.4	0.0	(0.4)
Others	20.1	24.6	4.5
Allowance for doubtful receivables	(0.4)	(0.4)	0.1
Total assets	393.0	382.5	(10.4)

− Effects of dissolving partnerships with Abbott Japan, etc. and shorter payback period

- Diversifying investments: Transferred to CPs ,bonds and long-term deposits

	Year ended 3/31/06	Year ended 3/31/07
Accounts receivable turnover period (in months)	4.27	4.08

LIABILITIES AND NET ASSETS

(Billions of Yen)

	As of 3/31/06 (A)	As of 3/31/07 (B)	(B) - (A)
Total liabilities	104.3	76.5	(27.8)
Current liabilities:	80.1	56.0	(24.0)
Notes and accounts payable	38.7	18.0	(20.7)
Income taxes payable	8.4	8.2	(0.2)
Reserve for bonuses	8.1	8.0	(0.0)
Reserve for sales returns	0.1	0.1	0.0
Reserve for sales rebates	0.6	0.5	(0.1)
Reserve for expenses related to litigation	—	1.0	1.0
Others	24.2	20.1	(4.1)
Long-term liabilities:	24.3	20.5	(3.8)
Long-term debt	5.3	4.6	(0.7)
Deferred tax liabilities	—	2.1	2.1
Reserve for retirement benefits	14.1	8.2	(5.9)
Reserve for directors' retirement benefits	0.1	0.1	(0.0)
Others	4.8	5.6	0.8
Net assets	288.6	306.0	17.4
Shareholders' equity	270.4	287.3	16.8
Common stock	22.4	22.4	—
Capital surplus	15.9	15.9	0.0
Retained earnings	232.5	249.5	17.0
Treasury stock	(0.3)	(0.5)	(0.1)
Valuation, transaction adjustments and others	17.3	17.8	0.5
Unrealized gains on available-for-sale securities	17.3	17.8	0.5
Minority interests	0.9	0.9	0.1
Total liabilities and net assets	393.0	382.5	(10.4)

- Effects of dissolving partnerships with Abbott Japan, etc.

- Repayment of borrowings, etc.

- Effects of pension plan integration, etc.

Note: Past year's results have been rearranged in the current period display section.

IV. Group-to-Parent Ratios, Consolidated Subsidiary, Number of Employees and MRs

1. Group-to-parent ratios for the year ended 3/31/07

(Billions of Yen)

	Consolidated	Non-consolidated	Variance	Group-to-parent ratio
Net sales	261.2	247.8	13.4	1.05
Operating income	45.6	45.3	0.3	1.01
Recurring income	43.2	42.9	0.3	1.01
Net income	22.6	22.5	0.1	1.00

2. Consolidated subsidiary (as of 3/31/07)

	Establishment date	Paid-in capital	Ownership ratio
Gokyo Trading Co., Ltd.	October 1947	¥100 million	52.48%

3. Number of employees (as of 3/31/07): 4,913 (consolidated); 4,834 (non-consolidated)

4. Number of MRs (as of 3/31/07): 1,470 (excluding managers); 1,700 (including managers)

V. Non-Consolidated Financial Highlights

1. Highlights of the Statements of Income (Billions of Yen)

	Year ended 3/31/06	Year ended 3/31/07	Change (%)	Year ending 3/31/08 (Forecast)	Change (%)	Six months ending 9/30/07 (Forecast)	Change (%)
Net sales	232.6	247.8	6.6	259.0	4.5	126.0	4.7
Cost of sales	119.0	87.6	(26.3)	90.0	2.7		
Selling, general and administrative expenses	85.0	114.9	35.2	123.4	7.4		
[R&D expenditures]	[29.7]	[40.9]	[37.8]	[48.0]	[17.4]		
Operating income	28.6	45.3	58.2	45.6	0.8	21.8	7.2
Recurring income	27.0	42.9	58.7	43.6	1.6	20.8	7.0
Net income	15.4	22.5	46.5	25.9	14.9	12.4	30.7

Note: Cost of Sales includes provision for (reversal of) reserve for sales returns.

Earnings per share (yen)	54.63	56.72	65.16

2. Highlights of the Balance Sheet (Billions of Yen)

	As of 3/31/06 (A)	As of 3/31/07 (B)	(B) - (A)
Total assets	387.4	376.4	(11.1)
Net assets	286.9	304.1	17.3
Shareholders' equity ratio	74.0%	80.8%	

Note: Past year's results have been rearranged in the current period display section.

VI. Shareholder Position (As of March 31, 2007)

1. Total number of authorized shares: 1,500,000,000

2. Total number of shares outstanding: 397,900,154 (Number of treasury stock 398,980)

3. Number of shareholders: 16,048

4. Major shareholders:

Shareholders	Status of Ownership	
	Shares owned	Investment ratio
	000 shares	%
Sumitomo Chemical Co., Ltd.	199,434	50.12
Inabata & Co., Ltd.	33,282	8.36
The Master Trust Bank of Japan, Ltd (Trust account)	14,312	3.60
Nippon Life Insurance Company	10,530	2.65
Japan Trustee Services Bank, Ltd. (Trust account)	9,931	2.50
Japan Trustee Services Bank, Ltd. (Trust account for Sumitomo Mitsui Banking Corporation's retirement benefits)	7,000	1.76
Sumitomo Life Insurance Company	5,776	1.45
Nissay Dowa General Insurance Co., Ltd.	4,928	1.24
BNY for GCM Client Accounts (E)ISG	4,192	1.05
The Dai-ichi Mutual Life Insurance Company	3,248	0.82

VII. Development Pipeline

Major Products under Development in Japan by DSP

Stage in JPN	Brand name/ Product code Formulation	Generic name	Therapeutic indications	Remarks
NDA filed	AD-5423 Oral	blonanserin	Schizophrenia	Developed in-house
	Oral	irbesartan	Hypertension	Originated by sanofi-aventis and sublicensed from Bristol-Myers K.K. for the Japanese market. Co-development with Shionogi for the Japanese market.
NDA filed New Indication	AD-810N Oral	zonisamide	Parkinson's disease	Developed in-house Approved indication: epilepsy (Trade name: EXCEGRAN®)
	SUMIFERON Injection	interferon-alfa (NAMALWA)	Compensated cirrhosis associated with chronic hepatitis C	In-licensed from GlaxoSmithKline Approved indications: chronic hepatitis C, renal cancer, etc.
NDA filed New Admin. Route	EPHEDRINE NAGAI Injection	ephedrine hydrochloride	Developed for *i.v.* injection Hypotension during anesthesia	Approved administration route: subcutaneous dose Co-developed with 2 other companies

Stage in JPN	Brand name/ Product code Formulation	Generic name	Therapeutic indications	Remarks
Phase III New Indication	MEROPEN (SM-7338) Injection	meropenem trihydrate	Febrile neutropenia	Developed in-house Approved indications: moderate to severe bacterial infections

Stage in JPN	Brand name/ Product code Formulation	Generic name	Therapeutic indications	Remarks
Phase II	AS-3201 Oral	ranirestat	Diabetic neuropathy	Developed in-house Co-developed with Kyorin Pharmaceutical in JPN
	SM-11355 Injection	miriplatin hydrate	Hepatocellular carcinoma	Developed in-house
	SM-13496 Oral	lurasidone	Schizophrenia	Developed in-house
	SMP-114 Oral	rimacalib	Rheumatoid arthritis	Developed in-house
	SMP-508 Oral	repaglinide	Diabetes	In-licensed from Novo Nordisk
	SMP-862 Oral	metformin hydrochloride	Diabetes	In-licensed from Merck Sante
	AC-3933 Oral	radequinil	Dementia	Developed in-house
Phase II New Indication	PRORENAL Oral	limaprost alfadex	Cervical spondylosis	Co-developed with Ono Pharmaceutical in JPN Approved indications: symptoms associated with thromboangitis obliterans and acquired lumbar spinal canal stenosis

[Main revisions since the announcement of February 2007]

SMP-536: Deleted because launched

Major Products under Development in Foreign Markets by DSP

Stage	Brand name/ Product code Formulation	Generic name	Therapeutic indications	Remarks
Phase III	AS-3201 Oral	ranirestat	Diabetic neuropathy	Developed in-house Phase III in the U.S. and Canada

Stage	Brand name/ Product code Formulation	Generic name	Therapeutic indications	Remarks
Phase II	SM-13496 Oral	lurasidone	Schizophrenia	Developed in-house Under preparation for Phase III in the U.S. and Europe, etc.
	SMP-114 Oral	rimacalib	Rheumatoid arthritis	Developed in-house Phase IIb in Europe
	AD-5423 Oral	blonanserin	Schizophrenia	Developed in-house Phase II in the U.S. and Europe
	AC-3933 Oral	radequinil	Dementia	Developed in-house Phase IIa in the U.S. and Europe
	SMP-986 Oral	Not determined	Overactive bladder syndrome	Developed in-house Phase II in the U.S. and Europe

Stage	Brand name/ Product code Formulation	Generic name	Therapeutic indications	Remarks
Phase I	SMP-028 Oral	Not determined	Bronchial asthma	Developed in-house Phase I in the U.S.

[Main revisions since the announcement of February 2007]

SM-13496 (lurasidone): Changed from consideration for Phase III to preparation for Phase III in the U.S. and Europe, etc.

Major Products under Development in Foreign Markets by Licensees

Generic / Product code (Brand name in JPN)	Therapeutic indications	Status of development
AG-7352	Cancer	Out-licensed to Sunesis Pharmaceuticals Inc. for the worldwide territory in October 2003 Phase II trials conducted by Sunesis (Sunesis' product code: SNS-595)
SMP-601	Life-threatening infection	Out-licensed to Protez Pharmaceuticals for the worldwide territory in May 2005 Protez Pharmaceuticals has started Phase I in Switzerland.
amrubicin hydrochloride SM-5887 (CALSED)	Cancer	Out-licensed to Pharmion (transferred from Cabrellis) for the European and U.S. territories in June 2005 Phase II conducted in the U.S. and Europe by Pharmion
ranirestat AS-3201	Diabetic neuropathy (Aldose reductase inhibitor)	Out-licensed to Eisai for the worldwide territory, excluding Japan, in September 2005. Phase III conducted in the U.S. and Canada by DSP Eisai will proceed with subsequent trials.

[Main revisions since the announcement of February 2007]

None

VIII. Profile of Major Products under Development

AD-5423 (blonanserin) Schizophrenia

- Developed in-house
- This drug blocks dopamine-2 receptors and serotonin-2 receptors. In clinical studies, this drug showed efficacy on not only positive symptoms of schizophrenia (such as hallucinations or delusions), but also negative symptoms (such as flat affect or hypobulia). The incidence of adverse reactions such as extrapyramidal symptoms or weight gain in the clinical studies was lower than the incidence reported for other drugs in this therapeutic area.
- Development stage: NDA filed in Japan. Phase II in the U.S. and Europe

Irbesartan Hypertension

- Originated by sanofi-aventis and sublicensed from Bristol-Myers K.K. for the Japanese market. Co-development with Shionogi for the Japanese market.
- The 6th ARB (Angiotensin II receptor blocker)
- Long-lasting stable anti-hypertension effect with renal and cardiac protection effect. Abundant data for efficacy and safety available.
- Development stage: NDA filed in Japan

AD-810N (zonisamide) Parkinson's disease (Additional therapeutic indication)

- Developed in-house
- Launched in June 1989 as an anti-epileptic drug (EXCEGRAN®), this drug has since been found to be useful in alleviating the symptoms of Parkinson's disease. This drug is believed to have a unique mechanism of action that is different from the mechanism of conventional anti-Parkinson's disease agents, most of which are dopamine receptor agonists.
- Development stage: NDA filed in Japan

AS-3201 (ranirestat) Diabetic neuropathy

- Developed in-house
- AS-3201 alleviates the symptoms of diabetic neuropathy, a complication of diabetes, by inhibiting aldose reductase and thereby inhibiting the accumulation of intracellular sorbitol that causes diabetic neuropathy. The inhibitory effect of this drug is stronger and longer acting than other drugs in this therapeutic area. In Phase IIa trials conducted overseas, AS-3201 showed good penetration into nerve tissue, resulting in dose-dependent inhibition of intraneural accumulation of sorbitol and fructose. Phase III trials are currently under way in North America to further investigate the utility of this drug in treating diabetic neuropathy. AS-3201 was out-licensed to Eisai for the overseas territory in September 2005.
- Development stage: Phase III in the U.S. and Canada. Phase II in Japan (co-developed with Kyorin Pharmaceutical)

SM-13496 (lurasidone) Schizophrenia

- Developed in-house
- SM-13496 is a potent dopamine-2 antagonist and antagonist against serotonin-2, -7 and 1A receptors. This drug is expected to have long-acting efficacy on schizophrenia with superior safety profile due to a reduced incidence of extrapyramidal reactions, cardiac reactions and weight gain.
- Development stage: Preparation for Phase III in the U.S. and Europe, etc. Phase II in Japan

SM-11355 (miriplatin hydrate)　　Hepatocellular carcinoma

- Developed in-house
- This drug is a lipid-soluble platinum complex that is suspended in Lipiodol and the suspension injected via a hepatic artery into the liver. By having it suspended in Lipiodol, the active substance of this drug is localized around the tumor and gradually released for a long time. This mechanism of action is expected to give this drug a high anti-tumor effect with reduced systemic adverse reactions.
- Development stage: Phase II in Japan

SMP-114 (rimacalib)　　Rheumatoid arthritis

- Developed in-house
- A new type of disease-modifying anti-rheumatic drug (DMARD) for oral administration, SMP-114 is expected to inhibit progression of rheumatoid arthritis, such as chronic inflammation and the destruction or deformation of joints.
- Development stage: Phase II in Europe. Phase II in Japan

SMP-508 (repaglinide)　　Diabetes

- In-licensed from Novo Nordisk
- SMP-508 stimulates pancreatic beta cells to release insulin. This drug is one of the rapid insulin secretion enhancing agents that act faster than conventional SU anti-diabetes drugs. By boosting insulin secretion to normal levels in type II diabetes patients whose insulin levels shortly after meals tend to be lower than normal, this drug is expected to suppress the postprandial elevation of blood glucose levels, resulting in lower blood glucose levels and HbAlc in fasting state.
- Development stage: Phase II in Japan

SMP-862 (metformin hydrochloride)　　Diabetes

- In-licensed from Merck Sante
- SMP-862 (metformin hydrochloride) is an anti-diabetic agent that lowers blood glucose levels by improving insulin resistance without enhancing insulin secretion. An oral formulation of metformin hydrochloride was first developed and launched as Melbin® in Japan by our company in 1961. Following the elucidation of the mechanism of action of metformin and with the accumulated findings from the large-scale clinical trials on this drug conducted in the U.S. and Europe, we believe that further information about the effect of this drug on Japanese patients should be collected to meet with the recent trend for evidence-based medicine. We are conducting clinical studies on Japanese patients so as to meet with the current regulatory requirement to approve a new indication with new dosage regimen for metformin.
- Development stage: Phase II in Japan

AC-3933 (radequinil)　　Dementia

- Developed in-house
- AC-3933 is a partial inverse agonist at benzodiazepine receptors, a mechanism of action markedly different from that of acetylcholinesterase inhibitors. This drug not only activates cholinergic neurons by enhancing the release of acetylcholine, but it also stimulates glutaminergic neurons. This drug is expected to improve memory impairment, a core symptom of dementia.
- Development stage: Phase II in the U.S. and Europe. Phase II in Japan

SMP-986　　Overactive bladder syndrome

- Developed in-house

- Besides antagonism of muscarinic receptors, SMP-986 also suppresses neural signals sent from the bladder to the central nervous system in cases of overactive bladder. The drug is expected to increase volume of micturition per visit, which in turn eases urinary urgency and reduces the frequency of both urination and incontinence. This drug is expected to have lower incidence of side effects, such as dry mouth, caused by the antagonism of muscarinic-3 receptors.
- Development stage: Phase II in the U.S. and Europe

SMP-028 Bronchial asthma

- Developed in-house
- SMP-028 suppresses a variety of inflammation-related leukocytes that are involved in the pathology of bronchial asthma. It is expected to become a treatment for asthma with a novel anti-inflammatory mechanism of action.
- Development stage: Phase I in the U.S.